Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6593439 | 0.86 | TSHR (0.58) | TSHRALDH1A1RAPGEF4L3MBTL1MAPK1 | |
| SCHEMBL9195842 | 0.86 | TSHR (0.73) | TSHRALDH1A1RAPGEF4L3MBTL1MAPK1 | |
| SCHEMBL2476648 | 0.85 | TSHR (0.56) | TSHRALDH1A1RAPGEF4L3MBTL1MAPK1 | |
| SCHEMBL2566000 | 0.82 | TSHR (0.54) | TSHRALDH1A1RAPGEF4L3MBTL1MAPK1 | |
| SCHEMBL5591566 | 0.81 | TSHR (0.53) | TSHRALDH1A1RAPGEF4L3MBTL1MAPK1 | |
| SCHEMBL9200936 | 0.80 | TSHR (0.52) | TSHRALDH1A1RAPGEF4L3MBTL1MAPK1 | |
| SCHEMBL11610732 | 0.80 | TSHR (0.55) | TSHRALDH1A1RAPGEF4L3MBTL1MAPK1 | |
| SCHEMBL1580297 | 0.80 | TSHR (0.52) | TSHRALDH1A1RAPGEF4L3MBTL1MAPK1 | |
| SCHEMBL9073778 | 0.80 | TSHR (0.52) | TSHRALDH1A1RAPGEF4L3MBTL1MAPK1 | |
| SCHEMBL25301888 | 0.80 | RAPGEF4 (0.54) | TSHRALDH1A1RAPGEF4L3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2664617-A1 | Method of making a 2,6-diaryl piperidine derivative | Genzyme Corporation (US) | 2013-11-20 | — | — | EP | disclosed |
| EP-1615633-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2374804-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | Genzyme Corporation (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20090281308-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED, INC. (CA) | 2009-11-12 | — | — | US | disclosed |
| US-7550484-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7501518-B2 | Methods of making 2,6-diaryl piperidine derivatives | GENZYME CORPORATION (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1615633-A4 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC (CA) | 2008-07-09 | — | — | EP | disclosed |
| EP-1809613-A2 | METHODS OF MAKING 2,6-DIARYL PIPERIDINE DERIVATIVES | ANORMED INC. (CA) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006049764-A2 | METHODS OF MAKING 2,6-DIARYL PIPERIDINE DERIVATIVES | ANORMED INC. (CA) | 2006-05-11 | — | — | WO | disclosed |
| EP-1615633-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2006-01-18 | — | — | EP | disclosed |
| US-20050154201-A1 | Methods of making 2,6-diaryl piperidine derivatives | ANORMED CORPORATION (CA) | 2005-07-14 | — | — | US | disclosed |
| US-20050059702-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2005-03-17 | — | — | US | disclosed |
| WO-2004093817-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154201-A1 | Methods of making 2,6-diaryl piperidine derivatives | ALDH7A1, DPYD, ALDH1A1 | TSHR 4710/4885ALDH1A1 3/4885RAPGEF4 1556/4885 |
| US-20050059702-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CXCR4, CXCR1, CCR5 | TSHR 1287/4885ALDH1A1 290/4885RAPGEF4 709/4885 |
| US-20090281308-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CXCR4, CXCR1, CCR5 | TSHR 1287/4885ALDH1A1 290/4885RAPGEF4 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.